Lindera aggregata intervents adenine-induced chronic kidney disease by mediating metabolism and TGF-β/Smad signaling pathway

Hongdie Cai,Juan Wang,Yiyuan Luo,Furong Wang,Guoqing He,Gen Zhou,Xin Peng
DOI: https://doi.org/10.1016/j.biopha.2020.111098
2021-02-01
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p><em>Lindera aggregata</em> is a main Chinese herb of ancient prescriptions Suoquan pill applied for treating the chronic kidney disease (CKD). A large number of application histories of <em>Lindera aggregata</em> in the treatment of CKD have been recorded in Chinese traditional medical literature. The previous reports revealed that <em>Lindera aggregata</em> can treat CKD.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Rats were randomly divided into control, model, Huangkui,<em>Lindera aggregata</em> ethanol extract (LEE) and <em>Lindera aggregata</em> water extract (LWE) groups. hematoxylin-eosin (HE) staining was used to detect the pathology of kidney. The levels of serum creatinine (Scr), serum Neutrophil gelatinase-associated lipocalin (NGAL), blood urea nitrogen (BUN), urine protein (UP), kidney index(KI) were evaluated. The UPLC − QTOF/MS were applied to probe the metabolic profile. Furthermore, Indoxyl sulfate-induced human renal tubular epithelial (HK-2) cell model was built to determine the expression levels of pathogenesis-related proteins.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The results demonstrated that LEE and LWE significantly inhibited the rebound in Scr, BUN, NGAL, UP and KI in models, except for the effect of LWE at low dose (LWE-L) and LEE at low dose (LEE-L) on KI and the effect of LWE-H at high dose (LWE-H) and LEE-L on BUN and NGAL. Moreover,<em>Lindera aggregata</em> extracts alleviated renal tubular dilatation, interstitial fibrosis and interstitial inflammation. By analysis, twenty-eight metabolites were related to CKD. After intervention of <em>Lindera aggregata</em> extracts, some metabolites approach to a normal-like level, such as Indoxyl sulfate. These metabolites are mainly involved in tryptophan, fatty acid, glycerophospholipid, tyrosine and arachidonic acid metabolic pathways. Furthermore, <em>Lindera aggregata</em> extracts mediate the expression of smad2, smad3, smad7 and TGF-β in Indoxyl sulfate-induced HK-2 cell.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p><em>Lindera aggregata</em> extracts can mitigate adenine-induced CKD by modulating the metabolic profile and TGF-β/Smad signaling pathway, providing important supports for developing protective agent of <em>Lindera aggregata</em> for CKD.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?